Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which
affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing …

Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis
(MS)(in particular the progressive forms) still represents an important unmet medical need …

The objective of this guideline is to provide healthcare professionals with clear, up‐to‐date
and practical guidance on the management of thrombotic thrombocytopenic purpura (TTP) …

Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system. The latest development of B-cell depletion by anti-CD20 monoclonal antibodies has …

Rituximab (375 mg/m2) achieved remission of the first episode and six relapses of nephrotic
syndrome (NS) in a young male patient with podocyte phospholipase A2 receptor (PLA2R) …

Background Rituximab is a chimeric anti-CD20 monoclonal antibody that induces sustained
remission in children with steroid-dependent nephrotic syndrome. However, there is no …

Rituximab, an anti‐CD20 monoclonal antibody, can be used to treat immune thrombotic
thrombocytopenic purpura (iTTP) during acute presentation or disease relapse. Undesirable …

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy secondary to a
severely decreased A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats …

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic
thrombocytopenic purpura (ITP) were investigated. We retrospectively analyzed 249 patients …

Modern therapy for acute TTP has resulted in a dramatic improvement in outcomes, with the
combination of plasma exchange, immunosuppression, and caplacizumab being associated …